Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company developing novel medicines for neurological diseases, has announced its participation in four major investor conferences in September 2024. The company will engage in various activities including:
- Hosting investor meetings at the Wells Fargo Healthcare Conference on September 5 in Boston
- Presenting a fireside chat and hosting meetings at the H.C. Wainwright Global Investment Conference on September 10 in New York
- Participating in a fireside chat and investor meetings at Baird's Global Healthcare Conference on September 11 in New York
- Delivering a fireside chat presentation and hosting meetings at the Cantor Global Healthcare Conference on September 17 in New York
Live webcasts of available presentations will be accessible on Longboard's website and archived for at least 30 days post-event.
Longboard Pharmaceuticals (Nasdaq: LBPH), una compagnia biofarmaceutica in fase clinica che sviluppa nuovi farmaci per malattie neurologiche, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori a settembre 2024. L'azienda sarà coinvolta in varie attività tra cui:
- Ospitare incontri con gli investitori alla Wells Fargo Healthcare Conference il 5 settembre a Boston
- Presentare una chiacchierata informale e ospitare incontri alla H.C. Wainwright Global Investment Conference il 10 settembre a New York
- Partecipare a una chiacchierata informale e incontri con investitori alla Baird's Global Healthcare Conference l'11 settembre a New York
- Fornire una presentazione in formato chiacchierata informale e ospitare incontri alla Cantor Global Healthcare Conference il 17 settembre a New York
Le dirette web delle presentazioni disponibili saranno accessibili sul sito di Longboard e archiviate per almeno 30 giorni dopo l'evento.
Longboard Pharmaceuticals (Nasdaq: LBPH), una compañía biofarmacéutica en etapa clínica que desarrolla nuevos medicamentos para enfermedades neurológicas, ha anunciado su participación en cuatro importantes conferencias para inversores en septiembre de 2024. La empresa participará en diversas actividades, incluyendo:
- Celebrar reuniones con inversores en la Wells Fargo Healthcare Conference el 5 de septiembre en Boston
- Presentar una charla informal y llevar a cabo reuniones en la H.C. Wainwright Global Investment Conference el 10 de septiembre en Nueva York
- Participar en una charla informal y reuniones con inversores en la Baird's Global Healthcare Conference el 11 de septiembre en Nueva York
- Realizar una presentación en formato de charla informal y llevar a cabo reuniones en la Cantor Global Healthcare Conference el 17 de septiembre en Nueva York
Las transmisiones en vivo de las presentaciones disponibles se podrán acceder en el sitio web de Longboard y se archivarán durante al menos 30 días después del evento.
롱보드 제약회사 (Nasdaq: LBPH)는 신경질환을 위한 새로운 약물을 개발하는 임상 단계의 생명공학 회사로, 2024년 9월에 4개의 주요 투자자 회의에 참여한다고 발표했습니다. 회사는 다음과 같은 다양한 활동에 참여할 예정입니다:
- 9월 5일 보스턴에서 열리는 웰스 파고 헬스케어 회의에서 투자자 회의를 주최합니다.
- 9월 10일 뉴욕에서 열리는 H.C. 웨인라이트 글로벌 투자 회의에서 화루 담소를 발표하고 미팅을 주최합니다.
- 9월 11일 뉴욕에서 열리는 베어드 글로벌 헬스케어 회의에서 화루 담소 및 투자자 회의에 참여합니다.
- 9월 17일 뉴욕에서 열리는 칸토 글로벌 헬스케어 회의에서 화루 담소 발표 및 미팅을 주최합니다.
제공되는 모든 발표의 라이브 웹캐스트는 롱보드의 웹사이트에서 접근 가능하며, 이벤트 이후 최소 30일 동안 아카이브됩니다.
Longboard Pharmaceuticals (Nasdaq: LBPH), une entreprise biopharmaceutique en phase clinique développant de nouveaux médicaments pour les maladies neurologiques, a annoncé sa participation à quatre grandes conférences d'investisseurs en septembre 2024. L'entreprise sera engagée dans diverses activités, y compris :
- Organiser des réunions avec des investisseurs lors de la Wells Fargo Healthcare Conference le 5 septembre à Boston
- Présenter une discussion informelle et organiser des réunions lors de la H.C. Wainwright Global Investment Conference le 10 septembre à New York
- Participer à une discussion informelle et à des réunions avec des investisseurs lors de la Baird's Global Healthcare Conference le 11 septembre à New York
- Fournir une présentation sous forme de discussion informelle et organiser des réunions lors de la Cantor Global Healthcare Conference le 17 septembre à New York
Les webdiffusions en direct des présentations disponibles seront accessibles sur le site web de Longboard et archivées pendant au moins 30 jours après l'événement.
Longboard Pharmaceuticals (Nasdaq: LBPH), ein biopharmazeutisches Unternehmen in der klinischen Phase, das neue Medikamente für neurologische Erkrankungen entwickelt, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im September 2024 bekannt gegeben. Das Unternehmen wird an verschiedenen Aktivitäten teilnehmen, darunter:
- Investorenmeetings auf der Wells Fargo Healthcare Conference am 5. September in Boston
- Präsentation eines Fireside Chats und Hosting von Meetings auf der H.C. Wainwright Global Investment Conference am 10. September in New York
- Teilnahme an einem Fireside Chat und Investorenmeetings auf der Baird's Global Healthcare Conference am 11. September in New York
- Durchführung einer Fireside Chat-Präsentation und Hosting von Meetings auf der Cantor Global Healthcare Conference am 17. September in New York
Live-Webcasts der verfügbaren Präsentationen sind auf der Website von Longboard zugänglich und werden mindestens 30 Tage nach der Veranstaltung archiviert.
- None.
- None.
CONFERENCE DETAILS:
Event: Wells Fargo Healthcare Conference
Details: Hosting investor meetings on Thursday, September 5, 2024, in
Event: H.C. Wainwright Global Investment Conference
Details: Presenting in a fireside chat format on Tuesday, September 10, 2024, at 12:00 PM ET and hosting investor meetings in
Event: Baird’s Global Healthcare Conference
Details: Presenting in a fireside chat format on Wednesday, September 11, 2024, at 10:50 AM ET and hosting investor meetings in
*This is intended for conference participants and will not be webcast
Event: Cantor Global Healthcare Conference
Details: Presenting in a fireside chat format on Tuesday, September 17, 2024, at 1:20 PM ET and hosting investor meetings in
Live webcasts of the available presentations will be added to the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The presentations will be archived on the website for at least 30 days following the events.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Earlier this year, Longboard reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants with DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. Longboard recently completed a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Bexicaserin and LP659 are investigational compounds that are not approved for marketing by the
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. In some cases, you can identify forward-looking statements by words such as “focus”, “will”, “upcoming”, “working to”, “designed to”, “plans”, “potential” or the negative, plural or other tenses of these words, references to future dates or time periods, or other comparable language, and they may include, without limitation, statements about Longboard’s conference participation, product candidates, clinical and preclinical programs, focus and work. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828664928/en/
CORPORATE CONTACT:
Megan E. Knight
VP, Head of Investor Relations
IR@longboardpharma.com
858.789.9283
Source: Longboard Pharmaceuticals, Inc.
FAQ
What investor conferences will Longboard Pharmaceuticals (LBPH) attend in September 2024?
When and where will Longboard Pharmaceuticals (LBPH) present at the H.C. Wainwright Global Investment Conference?
Will Longboard Pharmaceuticals' (LBPH) presentations at the September 2024 conferences be available online?
What type of company is Longboard Pharmaceuticals (LBPH)?
